About

Our story

Navari is a MedTech Startup located in Gothenburg, Sweden, developing a visualization technology for minimally invasive cancer surgery, with the aim of facilitating the transition from open surgery. The company originated as an innovative technology spinout from Chalmers University of Technology and Sahlgrenska University Hospital in Gothenburg, Sweden. Initially conceived as a multidisciplinary project between the two universities, the project underwent validation and was then introduced to Chalmers School of Entrepreneurship, where current CEO and COO first became involved. Their commitment and vision for the project’s future led to the formal incorporation of Navari in June 2021.

Currently, Navari is developing its first product which is dedicated to the initial target market of liver cancer.

Originating from clinical need

The concept behind Navari’s technology originates from MD/PhD. Niclas Kvarnström and his daily challenges when locating- and operating cancer tumors during minimally invasive liver surgery. The limited visibility during such surgeries significantly complicates the procedures and represents a fundamental obstacle in the broader adoption of minimally invasive cancer surgery. Together with MD/Prof. Mårten Falkenberg, Dr. Kvarnström began exploring various solutions to this problem and quickly realized that there were no suitable products available on the market. This realization sparked the idea of developing an augmented reality tool to better overcome these hurdles. Collaborating with mathematics experts Prof. Klas Modin and Prof. Torbjörn Lundh, they laid the groundwork for what is known today as Navari.

Current status

2022

Patent filed

In 2022, Navari filed its first patent for the completely novel single-use device. A second patent, relating to the Navari technology system, was filed in April 2024.

2022

Pre-seed

In October 2022, Navari closed a pre-seed investment of 7.5 MSEK, with the aim of developing the technology further and validating it in a preclinical study.

2023

PoC in vivo

In September 2023, Navari successfully conducted a preclinical study, validating the technology and achieving Proof of Concept in vivo.

Team

Madeleine Gustavsson

CEO

Madeleine has a BSc in product development and a MSc in Business Development & Entrepreneurship, as well as several years of working experience in the MedTech industry.

Axel Blomé

Coo

Axel has a background in engineering which with a Master’s degree in Business Development & Entrepreneurship, combines engineering and structure with business acumen.

Niclas Kvarnström

Clinical

Niclas is one of the most renowned transplant surgeons, with expertise in both laparoscopy and robotic surgery.